In 2005, the global incidence of gastroesophageal cancers was estimated at 1,500,000 new cases (500,000 esophageal and 1,000,000 gastric), with a prospect of 2,110,000 new cases by 2025.


France is particulary affected, with an incidence of oesophageal cancer that was the highest in Europe in 2011, with 4280 new cases, and 6440 gastric cancers. The prognosis in these cancers is particularly bleak, with overall survival at 5 years of only 5-10% for oesophageal cancers and of 25% for gastric cancers. Many arguments lead us to consider both oesophageal and gastric cancers together in the present project.

While surgery is the standard treatment for cancers at a curative stage, it is insufficient by itself in most cases to provide prolonged survival. Associated therapies which are frequently required in conjunction with surgery include endoscopy, chemotherapy, radiotherapy and targeted therapies. Although survival has improved, most patients still present with

  • advanced disease at diagnosis,
  • a poor or incomplete response to treatment, aux traitements,
  • early recurrence,
  • an impaired quality of life.

At present the approach to treatment is a not individualised, it rarely takes account of subgroups of patients and most often occurs within the setting of clinical trials that seek to answer a specific question. Moreover, compared to other cancers, research in OG cancer is much less developed with a relative disinterest from industry.

It is therefore imperative to increase research into these types of tumours and to develop a broad and ambitious mechanism through which the scientific questions of today and tomorrow may be answered. This research must take a personalised approach to identify clinical, laboratory and tumour related factors associated with treatment resistance, whilst seeking to explain the epidemiological and social facets of disease behaviour.

The creation of a national prospective database, dedicated to patients with carcinomas of the oesophagus and stomach, and which includes epidemiological, clinical, tumour related, follow-up and social sciences and quality of life data, in conjunction with a tumour and serum bank, is consequently a major and indispensable tool for France.

Financial support :

Lorem ipsum : Pellentesque pellentesque eget tempor tellus. Fusce lacllentesque eget tempor tellus ellentesque pelleinia tempor malesuada. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Sunt dignissimos, autem quaerat dolorem maiores placeat!